779 patents
Page 23 of 39
Utility
Chemical Compounds
24 Jun 21
Scott William Bagley, Agustin Casimiro-Garcia, Xiayun Cheng, Jennifer Elizabeth Davoren, Rajiah Aldrin Denny, Brian Stephen Gerstenberger, Frank Eldridge Lovering, Mihir Dineshkumar Parikh, Joseph Walter Strohbach, John Isidro Trujillo
Filed: 18 Dec 20
Utility
Therapeutic Nanoparticles Comprising A Therapeutic Agent And Methods of Making and Using Same
24 Jun 21
The present disclosure generally relates to nanoparticles comprising an antibody, such as an anti-PD-1 antibody.
Stephen E. Zale
Filed: 10 Feb 17
Utility
Therapeutic Antibodies and Their Uses
24 Jun 21
The present invention relates bispecific antibodies that specific binds to BCMA (B-Cell Maturation Antigen) and CD3 (Cluster of Differentiation 3).
Tracy Chia-Chien KUO, Javier Fernando CHAPARRO RIGGERS, Wei CHEN, Amy Shaw-Ru CHEN, Edward Derrick PASCUA, Thomas John VAN BLARCOM, Leila Marie BOUSTANY, Weihsien HO, Yik Andy YEUNG, Pavel STROP, Arvind RAJPAL
Filed: 21 Dec 20
Utility
Anti-proliferative Agents for Treating Pah
24 Jun 21
Pulmonary hypertension and related diseases, like pulmonary arterial hypertension, can be treated by administering an effective dose of a CDK inhibitor, including palbociclib, 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one, or pharmaceutically acceptable salt thereof.
Steven Martin Evans
Filed: 4 Nov 20
Utility
Orally Administered Combinations of Amoxicillin and Avibactam Derivatives for Treating Mycobacterial Infections
24 Jun 21
Pharmaceutical compositions comprise amoxicillin and an avibactam derivative and methods of treating bacterial infections using the pharmaceutical compositions.
JOAQUIM TRIAS
Filed: 16 Dec 20
Utility
Therapeutic Nanoparticles Comprising a Therapeutic Agent and Methods of Making and Using the Same
17 Jun 21
The present disclosure generally relates to nanoparticles comprising a substantially hydrophobic acid and a therapeutic agent (1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea), or pharmaceutically acceptable salts thereof, and a polymer.
Shubha Bagrodia, Jennifer Lafontaine, Zach Lovatt, Eyoung Shin, Young Ho Song, Greg Troiano, Hong Wang
Filed: 24 Feb 21
Utility
Antibodies Specific for CD47, PD-L1, and Uses Thereof
17 Jun 21
Antibodies that specifically bind to CD47 and antibodies that specifically bind to PD-L1 are provided, as well as CD47/PD-L1 bispecific antibodies.
Javier Fernando CHAPARRO RIGGERS, Shih-Hsun CHEN, Sheng DING, Pawel Kamil DOMINIK, Shahram SALEK-ARDAKANI, Jessica Lynn Stanfield, Thomas John VAN BLARCOM
Filed: 14 Dec 20
Utility
Media and Fermentation Methods for Producing Polysaccharides In Bacterial Cell Culture
17 Jun 21
The present invention relates to media and fermentation methods for producing polysaccharides in bacterial cell culture.
Sunil Gururao Desai, Michael Allen Hanson, Jonathan Patrick Kinross, Daniel R. Lasko, Scott Ellis Lomberk, Jason Arnold Lotvin, Sujata Kaushikbhai Patel-Brown, Weiqiang Sun, Peter Anthony Tomasello
Filed: 8 Feb 21
Utility
Diacylglycerol acyl transferase 2 inhibitors
15 Jun 21
Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
Markus Boehm, Shawn Cabral, Matthew S. Dowling, Kentaro Futatsugi, Kim Huard, Esther Cheng Yin Lee, Allyn T. Londregan, Jana Polivkova, David A. Price, Qifang Li
Filed: 18 Feb 20
Utility
4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors
8 Jun 21
Shelley Allen, Mark Laurence Boys, Mark J. Chicarelli, Jay Bradford Fell, John P. Fischer, John Gaudino, Erik James Hicken, Ronald Jay Hinklin, Christopher F. Kraser, Ellen Laird, John E. Robinson, Tony P. Tang, Laurence E. Burgess, Robert Andrew Rieger, Jed Pheneger, Yoshitaka Satoh, Katerina Leftheris, Raj K. Raheja, Brydon L. Bennett
Filed: 2 Jun 20
Utility
GLP-1 Receptor Agonists and Uses Thereof
3 Jun 21
Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
Gary Erik Aspnes, Scott W. Bagley, John M. Curto, David James Edmonds, Mark E. Flanagan, Kentaro Futatsugi, David A. Griffith, Kim Huard, Yajing Lian, Chris Limberakis, Allyn T. Londregan, Alan M. Mathiowetz, David W. Piotrowski, Roger B. Ruggeri
Filed: 9 Feb 21
Utility
Interferon Beta Antibodies and Uses Thereof
3 Jun 21
The invention relates to antibodies, or antigen-binding fragments thereof, that specifically binds to interferon beta (IFNβ).
Stefano V. Gulla, Christine Huard, Janet Elizabeth Buhlmann, Juan Carlos Almagro, Sreekumar R. Kodangattil, Steven A. Greenberg, Edward Roland Lavallie, Eric M. Bennett, Lidia Mosyak, James Perry Hall, Anthony John Coyle
Filed: 9 Nov 20
Utility
Soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides and uses thereof
1 Jun 21
The invention features soluble fibroblast growth factor receptor 3 (sFGFR3) polypeptides.
Elvire Gouze, Stéphanie Garcia
Filed: 20 May 19
Utility
Crystalline form of lorlatinib free base
1 Jun 21
This invention relates to acrystalline form of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-5-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h] [2,5,11]benzoxadiazacyclo-tetradecine-3-carbonitrile (lorlatinib) free base (Form 7).
Klimentina Dimitrova Pencheva, Melissa Jane Birch, Stephen Mark McAllister, Martin Gregory Rowland, Ian Leonard Smales
Filed: 8 Aug 19
Utility
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
1 Jun 21
The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof.
Wendy Jo Watson, Luis Pascual Jodar Martin-Montalvo, Raul Enrique Isturiz, Ralf Rene Reinert
Filed: 25 Sep 18
Utility
Chemical compounds
25 May 21
Ariamala Gopalsamy, Arjun Venkat Narayanan, Agustin Casimiro-Garcia, Chulho Choi, David Hepworth, David Walter Piotrowski, Hatice Gizem Yayla, Jayasankar Jasti, Lee Richard Roberts, Lyn Howard Jones, Mihir Dineshkumar Parikh, Ming Zhu Chen, Olugbeminiyi Omezia Fadeyi, Ralph Pelton Robinson, Jr., Robert Lee Dow, Shawn Cabral
Filed: 26 Nov 19
Utility
Heteroaromatic compounds and their use as dopamine D1 ligands
25 May 21
Michael Aaron Brodney, Jennifer Elizabeth Davoren, Amy Beth Dounay, Ivan Viktorovich Efremov, David Lawrence Firman Gray, Michael Eric Green, Jaclyn Louise Henderson, Chewah Lee, Scot Richard Mente, Steven Victor O'Neil, Bruce Nelsen Rogers, Lei Zhang
Filed: 21 May 20
Utility
CDK2 inhibitors
25 May 21
Douglas Carl Behenna, Kevin Daniel Freeman-Cook, Robert Louis Hoffman, Asako Nagata, Sacha Ninkovic, Scott Channing Sutton
Filed: 28 Jan 20
Utility
Group B Streptococcus Polysaccharide-protein Conjugates, Methods for Producing Conjugates, Immunogenic Compositions Comprising Conjugates, and Uses Thereof
20 May 21
The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B. streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%.
Annaliesa Sybil Anderson, Amardeep Singh Bhupender Bhalla, Robert G.K. Donald, Jianxin Gu, Kathrin Ute Jansen, Rajesh Kumar Kainthan, Lakshmi Khandke, Jin-Hwan Kim, Paul Liberator, Avvari Krishna Prasad, Mark Edward Ruppen, Ingrid Lea Scully, Suddham Singh, Cindy Xudong Yang
Filed: 28 Jan 21
Utility
Mutant Antibodies and Conjugation Thereof
20 May 21
The present invention relates to a polypeptide comprising 7 β-strands A, B, C, D, E, F, and G sequentially connected together by connecting chains of amino acids, and a first α-helix sequentially located on the EF chain between β-strands E and F, wherein the β-strands are arranged so as to form a first β-sheet comprising β-strands A, B, D, and E, and a second β-sheet comprising β-strands C, F and G, said first and second β-sheets being covalently bonded together so as to form a first Ig domain; wherein the EF chain between β-strands E and F comprises the sequence X1-X2-X3-X4-K5H6 (SEQ ID NO:98), and X1, X3 and X4 are each independently any amino acid residue, characterized in that X2 is selected from the group consisting of A, G, I, V, L, R, S, T, Q, P, N, M, H, W, and pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, and prodrugs thereof
Olivier Alexandre Laurent, Alice Lee, Richard Ryan Preston, David Tumelty, Wei Hong Yu, Abhijit Suresh Bhat, Anna Tempczyk-Russell
Filed: 9 Jun 20